SERx – 400 Series

We have also developed a SERx – 400 series that exhibits a different, but complementary, pharmacological profile that has potential for treating additional symptoms that often accompany Fragile X syndrome and other autistic disorders. Our SERx – 400 series selectively enhances 5-HT2C signaling while reducing 5-HT2A/2B signaling. As with our SERx – 500 series, this represents a first-in-class pharmacological profile and we believe that our SERx – 400 lead, SERx  480, has potential to address cognitive dysfunction, attention deficit, hyperactivity, and psychosis associated with Fragile X syndrome and autism. We anticipate that SERx  480 will not produce the sedative or weight gain side effects that typically accompany other antipsychotic drugs frequently used in Fragile X patients.


SERx -400 series balanced neuromodulatory activity (5HT2C activation, 5HT-2A/2B inactivation)  translates to beneficial effects on memory, learning, and cognitive function.


SERx – 400 Series: First-in-Class 5-HT2C Agonist with 5-HT2A/2B Inverse Agonist Activity

SERx – 480 demonstrates efficacy in an in vivo mouse model of hallucinogen psychosis.

SERx drug candidates have activity to reduce impulsive and compulsive behaviors that frequently occur in Fragile X syndrome. For example, SERx –480 blocks impulsive/compulsive behavior in a mouse binge-eating model (Journal of Pharmacology and Experimental Therapeutics 2014, Vol 349, pages 310-318).

In contrast to other antipsychotic drugs, including, aripiprazole that is used to treat irritability in autism spectrum disorder, SERx – 480 demonstrates no sedative effect in an in vivo mouse model of sedation.

In rodent model of obsessive-compulsive disorder cognitive impairment (ADHD), SERx-480 selectively increases attention (observing response vs. food response), similar to amphetamine. Our SERx-400 series compounds are as effective as amphetamines in the ADHD mouse models and they have a significantly improved safety profile.